Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double homeobox A pseudogene 1 (DUXAP1)
- Target
- DUXAP1
- Molecular classification
- Other, Long non-coding RNA (lncRNA) pseudogene
01
Overview
Double homeobox A pseudogene 1 (DUXAP1) is a long non-coding RNA pseudogene implicated as an oncogenic driver in multiple malignancies, with key roles in promoting cell proliferation, migration, invasion, and chemotherapy resistance. In hepatocellular carcinoma specifically, DUXAP1 acts as a ceRNA by sequestering miR-584-5p, thereby upregulating MAPK1 (ERK2) and activating the MAPK/ERK pathway, which contributes to increased malignancy and drug resistance. DUXAP1 expression is upregulated via m6A methylation and is positively associated with tumor progression, recurrence, and poor clinical outcomes.
- Other names
- DUXAP1double homeobox A pseudogene 1
02
Mechanism of action
DUXAP1 acts as a molecular sponge for miR-584-5p via ceRNA mechanism, upregulating MAPK1 (ERK2) and activating MAPK/ERK signaling, thereby promoting malignant phenotype and drug resistance.
03
Biological functions
Regulation of cell proliferationPromotion of cell migration and invasionEnhancement of drug resistance (specifically chemotherapy resistance in hepatocellular carcinoma)Regulation of cancer stemness pathwaysOncogenic ceRNA (competitive endogenous RNA) regulatory function
04
Disease associations
Cancer (especially hepatocellular carcinoma, HCC)Therapy resistance (chemotherapy resistance)Tumor growth and metastasis (e.g., increased migration, invasion, and stemness markers in malignancy)
05
Safety considerations
Targeting lncRNAs such as DUXAP1 poses challenges including off-target effects, lack of protein knockdown specificity, and potential systemic toxicity due to regulatory network complexity
06
Interacting drugs
Sorafenib
07
Biomarkers
DUXAP1 (expression is correlated with HCC progression, metastasis, and chemoresistance)MAPK1 (as downstream effector of DUXAP1-driven pathway)Stemness genes: CD133, OCT4, NANOG, Sox2 (their expression is influenced by DUXAP1 activity)
Beyond the preview
Go deeper on Double homeobox A pseudogene 1 (DUXAP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Double homeobox A pseudogene 1 (DUXAP1).